Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PALBOCICLIB vs RUXOLITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

PALBOCICLIB vs RUXOLITINIB: Safety Overview

Metric PALBOCICLIB RUXOLITINIB
Total FAERS Reports 91,024 68,133
Deaths Reported 11,066 10,908
Death Rate 12.2% 16.0%
Hospitalizations 13,442 14,461
Average Patient Age 66.0 yrs 59.7 yrs
% Female Patients 97.7% 48.8%
FDA Approval Date Feb 3, 2015 Nov 16, 2011
Manufacturer Pfizer Laboratories Div Pfizer Inc Incyte Corporation
Route ORAL TOPICAL
Marketing Status Prescription Prescription